UK markets close in 2 hours 38 minutes
  • FTSE 100

    7,275.24
    +52.42 (+0.73%)
     
  • FTSE 250

    23,072.79
    +131.01 (+0.57%)
     
  • AIM

    1,230.20
    +1.19 (+0.10%)
     
  • GBP/EUR

    1.1880
    +0.0027 (+0.22%)
     
  • GBP/USD

    1.3805
    +0.0036 (+0.26%)
     
  • BTC-GBP

    45,341.34
    -373.11 (-0.82%)
     
  • CMC Crypto 200

    1,503.77
    +1,261.09 (+519.65%)
     
  • S&P 500

    4,566.48
    +21.58 (+0.47%)
     
  • DOW

    35,741.15
    +64.13 (+0.18%)
     
  • CRUDE OIL

    84.10
    +0.34 (+0.41%)
     
  • GOLD FUTURES

    1,797.80
    -9.00 (-0.50%)
     
  • NIKKEI 225

    29,106.01
    +505.60 (+1.77%)
     
  • HANG SENG

    26,038.27
    -93.76 (-0.36%)
     
  • DAX

    15,756.80
    +157.57 (+1.01%)
     
  • CAC 40

    6,763.49
    +50.62 (+0.75%)
     

Moderna Slips As Issues At Partners Delay Overseas Release Of Shots

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Dhirendra Tripathi

Investing.com – Moderna (NASDAQ:MRNA) stock fell more than 4% as the company said issues at its manufacturing partners’ end have slowed down the release of Covid-19 vaccines to countries outside the U.S.

According to Bloomberg, Moderna’s manufacturing partners outside the U.S. are “facing delays” due to laboratory testing issues that occurred in recent days.

While the problem has been resolved, it has slowed release of Moderna’s vaccine to markets outside the U.S., Bloomberg said.

The news agency reported that the company is shipping shots as it makes them and has no extra shots on hand.

Earlier in the day, Reuters reported that Moderna had pushed back its late-July shipments for South Korea to August due to supply problems that will affect other countries as well.

The supply issue is linked to the vaccine manufacturing process involving Switzerland’s contract drugmaker Lonza (SIX:LONN) and a Spain-based company which does bottling work for the Moderna vaccine, the Reuters report quoted Jung Eun-young, head of the vaccine procurement team in South Korea, as saying.

She did not name the firm, but, according to Reuters, Spanish company Rovi (MC:ROVI) bottles, or "fills and finishes," Moderna vaccines for markets other than the U.S.

Related Articles

Moderna Slips As Issues At Partners Delay Overseas Release Of Shots

3 Things Investors Need to Know About the 4th Pandemic Wave

4 Mid-Cap Semiconductor Stocks That Have More Room to Run

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting